# John Putters on how the AI driven WANDA™ from Visionstate is Changing the Standards for Cleanliness in Facility Management

written by InvestorNews | January 16, 2024
In a recent Investor.Coffee interview with host Tracy Weslosky, John Putters CEO of [Visionstate Corp.](#) (TSXV: VIS) discussed the growing need for effective cleaning protocols to prevent disease outbreaks and how **WANDA™** has the potential to change standards for facility management cleanliness from airports to restaurants.

Specifically, they discuss the most [recent deal](#) that Visionstate IoT Inc., a subsidiary of Visionstate Corp., has entered into with Bunzl Canada Inc. This 3-year deal assigns Bunzl Canada the exclusive rights to distribute Visionstate's WandaNEXT product in Canada, Australia, and the UK. Concurrently, Visionstate IoT will manage direct sales of WandaNEXT in the U.S. through its internal sales team. This partnership is a strategic move for Visionstate, positioning them for further expansion in the international facility-management sector. The contract's implications are substantial, particularly in the Canadian market, where it is anticipated to increase Visionstate's existing revenue.

WandaNEXT, the flagship product of Visionstate, is an innovative AI-driven application widely utilized across various sectors to monitor and enhance cleaning protocols, thereby improving overall efficiency in building services. The technology has been

pivotal in elevating the standards of cleanliness and operational excellence, marking a significant advancement in the facility management industry.

The collaboration between Visionstate Corp. and Bunzl Canada extends beyond mere distribution rights. It encompasses a revenue-sharing arrangement across the three territories and involves joint efforts in the continued development and enhancement of the WandaNEXT platform. John Putters, the CEO of Visionstate Corp., expressed enthusiasm about the extended partnership with Bunzl Canada. He highlighted the contract's importance in aligning with Visionstate's strategic objectives and strengthening its position in the global market. For more information, [click here](#)

Don't miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by [clicking here](#)

## About Visionstate Corp.

Visionstate Corp. (TSXV: VIS) is a growth-oriented company that invests in the research and development of promising new technology in the realm of the Internet of Things, big data and analytics, and sustainability. Visionstate IoT Inc. is a wholly-owned subsidiary of Visionstate Corp. Through Visionstate IoT Inc., it helps businesses improve operational efficiencies, reduce costs, and elevate customer satisfaction with its state-of-the-art devices that track and monitor guest activities and requests. The footprint of its WANDA™ smart device now extends to hospitals, airports, shopping centres, and other public facilities across and beyond North America. Through building up a collection of synergistic technologies, Visionstate Corp. will continue to innovate, reduce environmental impact, and transform consumer experiences.

To learn more about Visionstate Corp., [click here](#)

---

# Andre Larente from DIAGNOS on Deal with World's Largest Eyecare Retailer EssilorLuxottica

written by InvestorNews | January 16, 2024

InvestorNews host Tracy Weslosky recently conducted an insightful interview with André Larente, President and Director of [DIAGNOS Inc.](DIAGNOS Inc.) (TSXV: ADK | OTCQB: DGNOF), to discuss the company's exclusive [distribution agreement](distribution agreement) with EssilorLuxottica. DIAGNOS, known for its pioneering FLAIRE

platform based on Artificial Intelligence (AI), has solidified its position as a leading provider of retinal analysis technology through this partnership. This agreement, announced on December 11th, is a significant milestone for DIAGNOS, signaling its growing influence in the AI and healthcare technical services sector.

During the interview, Larente highlighted the capabilities of DIAGNOS' AI-powered retinal image analysis technology, which has been acclaimed for its role in the early detection of various eye conditions. This breakthrough technology not only enhances the quality of eye health care but also significantly impacts patient lives positively. The partnership with EssilorLuxottica, a global leader in vision care with an $87Bn market cap, is set for an initial three-year term with potential for renewal.

Under the agreement, DIAGNOS will be compensated on a per patient exam basis across EssilorLuxottica's client network. Larente expressed his pride in the partnership, emphasizing the pivotal role it plays in DIAGNOS' mission to broaden the accessibility of its retinal analysis technology. This collaboration is expected to contribute significantly to visual health in Canada and potentially the USA. Both DIAGNOS and EssilorLuxottica are committed to advancing eye health and technology, with a focus on offering innovative solutions to optometrists that will transform the early detection and quality of eye care in the region.

In summary, DIAGNOS' exclusive distribution agreement with EssilorLuxottica marks a key development in its journey, reinforcing its commitment to revolutionizing eye health care through advanced AI-based technologies. This collaboration is set to make a profound impact on the early detection and treatment of eye conditions, benefiting a wide range of patients and healthcare providers.

To access the complete interview, [click here](#)

Don't miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by [clicking here](#)

**About DIAGNOS Inc.**
DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

To learn more about DIAGNOS Inc., [click here](#)

---

# Applying AI for the good of humanity, a tool for early detection of preventable blindness in diabetes patients is here

written by InvestorNews | January 16, 2024

Is Artificial Intelligence (AI) going to save the world? Likely not if you are a fan of the Terminator series made famous by Arnold Schwarzenegger or the Dune novels written by Frank Herbert, amongst other potential humanity ending scenarios. But until AI becomes self-aware, there is certainly a lot of good the data processing and analysis tools provided through machine learning can do to help humanity achieve significant improvements to our health and well-being until we all become slaves to our computer overlords.

One publicly traded company using AI that doesn't already have a Trillion dollar market cap is [DIAGNOS Inc.](#) (TSXV: ADK | OTCQB: DGNOF). DIAGNOS is a Canadian corporation dedicated to the early detection of critical health problems based on its FL*AI*RE Artificial Intelligence (AI) platform. FL*AI*RE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients. CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).

DIAGNOS primarily markets CARA as a software platform which

assists health specialists in the detection of diabetic retinopathy. [Diabetic retinopathy](#) (also referred to as macular edema) is a diabetes complication that affects the eyes. It's caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). At first, diabetic retinopathy might cause no symptoms or only mild vision problems, but it can lead to blindness. The condition can develop in anyone who has type 1 or type 2 diabetes.

A patient may experience no symptoms of diabetic retinopathy until the condition becomes severe. Early detection and treatment can prevent 85% to 95% of blindness cases. Thus it makes a lot of sense that everyone with diabetes gets screened for diabetic retinopathy at least once a year due to the fact that it is estimated that up to 347,000 people every year could go blind from a curable disease if they aren't screened early enough. This seems like a very good use of AI for the betterment (and not enslavement) of humanity.

In February, DIAGNOS and École de Technologie Supérieure (ÉTS), a world-renowned technical university [announced](#) that they would be presenting the results of their ground-breaking research on mass screening for macular edema using Optical Coherence Tomography (OCT) at ARVO 2023, the Annual Conference of the Association for Research in Vision and Ophthalmology (ARVO). The screening process for macular edema has been revolutionized by the research carried out by DIAGNOS and ÉTS, resulting in impressive efficiency of algorithms, fidelity of the "heat map" type decision-making tool, and an extremely low rate of "false positives." It is anticipated that DIAGNOS' AI-enabled screening process could become the go-to method adopted by healthcare professionals in the future.

I'm not worried about the AI being deployed by DIAGNOS taking over the world anytime soon. However, I am excited to see where

this Company goes next. I can't help but think it's a good thing to become the de facto tool for early detection of preventable blindness in diabetes patients. That's got to be worth something. But there's also the springboard of having a successful platform in place to build off of. Time will tell if this AI story starts making headlines with all the rest of them out there.

DIAGNOS Inc. trades at a market cap of C$35 million.

---

# NetraMark is Unleashing the Power of Artificial Intelligence to Revolutionize the Pharmaceutical Industry

written by InvestorNews | January 16, 2024

The market is awash with the talk of Artificial Intelligence (AI) and Machine Learning (ML). The most recent quarter of tech earnings had many of the "big guys" (Apple, Alphabet/Google, Microsoft, Meta) talking about their AI capabilities and where it was leading them.

In fact, just yesterday Alphabet Inc.'s (NASDAQ: GOOGL) stock surged as much as 5% after it made several AI announcements at its developer conference.

Microsoft Corporation (NASDAQ: MSFT) has invested in ChatGPT, which seems to have helped its share performance this year.

And despite the dire warnings of Elon Musk, Steve Wozniak, and the "godfather of AI" Geoffrey Hinton, it seems AI is sparking a bit of an investment frenzy, at least until something else comes along to capture the market's attention.

## AI: A Complex and Diverse Field

However, AI isn't exactly a definitive thing. Simply stating you are using AI is a little bit like saying I'm going on a holiday. You don't know where I'm going, how I'm getting there, or what I plan to do on my holiday.

It's one thing to use AI to generate a viral video that sounds like a [collaboration between Drake and The Weeknd](#) and another thing to do something useful (although you may argue a viral video is a useful thing).

Even more granular, you can have an industry that is using AI to advance technology or improve efficiency but still have very different approaches or algorithms tackling a variety of unique issues. In other words, an article on AI could be way longer than anything I intend to discuss today.

Instead, I'm simply going to have a look at one example of how a company is putting its own twist on AI for the benefit of humanity and hopefully its investors.

## NetraMark Holdings – A Unique Approach to AI in the Pharmaceutical Industry

That company is [NetraMark Holdings Inc.](#) (CSE: AIAI). NetraMark is a software technology company dedicated to improving the understanding of how patients, within and across diseases, relate to each other through the integration of multiple types of data via unique AI-enhancing software targeted at the Pharmaceutical industry. Its product offering uses a novel

topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. And hopefully, that's as complex a sentence as there is in this article.

NetraMark is addressing a market where less than 12% of the candidate medicines successfully make it through the clinical trial process and receive approval from the FDA. Given all the unsuccessful biotech companies I've participated in, I find that a very easy statistic to believe.

NetraMark is utilizing its proprietary AI algorithm to review where trials have failed and improve the success rate (see the complex sentence above). In other words, just because a specific trial might have failed, it doesn't mean the drug candidate wasn't successful, it might just be that it isn't successful for certain people but wildly successful for others. The challenge becomes using AI to figure this out.

## NetraMark's Focus on Small Data Sets

Over 95% of drug trials have less than 1,000 people participating in them, which is a pretty small data set. Typically small data sets aren't conducive to the use of AI.

Where NetraMark is unique is that Founder, Chief Scientific and Technology Officer, Dr. Joseph Geraci has spent over 5 years developing AI algorithms that focus on deriving statistically relevant findings in small data sets. Their product provides an intuitive interface for scientists to interact with small datasets to uncover connections related to efficacy, toxicity, and placebo response. The Company has [published numerous White Papers](#) on how their technology has identified various insights on topics ranging from pancreatic cancer to Alzheimer's disease progression to lung cancer.

## Potential for Growth

And the best part for investors is, this isn't something that is still in development. It's functional and running today. Last week [NetraMark announced](#) the completion of a recent client engagement to utilize outcome data collected in Phase 3 clinical trials from a specialty biopharma company. This was part of a Master Service Agreement whereby the Company earned a fixed fee for a defined Scope of Work.

NetraMark is guiding toward contracts valued at C$2 to C$3 million for the current fiscal year and C$7 to over C$9 million for next year.

## Acquisitions in the AI Drug Discovery Space

Of course, that assumes the Company even makes it until next year. On Monday of this week, [Recursion Pharmaceuticals, Inc.](#) (NASDAQ: RXRX), a leading clinical-stage biotech company [announced](#) it has signed agreements to acquire two companies in the AI drug discovery space: [Cyclica Inc.](#) and [Valence Discovery](#).

What makes this relevant? In February 2022, [NetraMark partnered with Cyclica Inc.](#) to accelerate drug discovery targeting neurodegenerative diseases.

Given Cyclica is a private company, it's hard to determine what type of multiple the $40 million price Recursion paid represents. But it does confirm that the AI frenzy is heating up.

What that means for NetraMark remains to be seen.

NetraMark Holdings trades at a current market cap of C$23 million.

## FIGURE 1: NetraMark Holdings — 1-Year Stock Chart

---

# AI Stocks to Watch as Investors Look to Ride the Next Technology Wave

written by InvestorNews | January 16, 2024

Fears of artificial intelligence in androids, massive computer facilities, and other devices taking over the world are not stopping investors from searching for ways to make prudent investments.

From AI and automation to robotics, nearly every industry is undergoing disruption. Over the past few months, the world has

witnessed significant advancements in AI technology, such as the release of chatbots and image, art, and music generators for public use.

# Generative Artificial Intelligence

Generative Artificial Intelligence (Gen AI) is a branch of artificial intelligence that uses machine learning algorithms to create new and original content, such as computer code, images, music, speech, or text. It works by using a training algorithm and 'learning' on a large dataset of examples, then using that training to generate new content that is similar to the original examples.

Most recently, the chatter around Gen AI has been brought to the forefront by the web-based Chat Generative Pre-trained Transformer, or as it is more widely known, ChatGPT, from [OpenAI, L.L.C.](#) OpenAI is a privately-held company with investors including [Microsoft Corporation](#) (Nasdaq: MSFT), [Khosla Ventures](#), [Y Combinator](#), and Guangzhou Cornerstone Asset Management Co.

It has many applications and benefits for various industries, such as entertainment, education, finance, health care, marketing, media, pharmaceuticals, and security.

Some of the leading public companies by market cap that operate in the broader AI and Gen AI industry are:

# Microsoft Corporation (Nasdaq: MSFT) — Market Cap US$2.20 Trillion

[Microsoft](#) offers cloud computing, software, and hardware products and services, such as Microsoft Azure and Microsoft Cognitive Services. Microsoft's Azure AI is a collection of AI services that offers developers and data scientists the ability to build and deploy their own AI solutions using high-quality

vision, speech, language, and decision-making AI models through simple API calls, and create their own machine learning models using familiar tools and open-source frameworks

## Alphabet Inc. (Nasdaq: GOOGL) — Market Cap US$1.32 Trillion

[Alphabet](), best known for its Google search engine, provides internet-related products and services, such as Google Cloud and Google AI. Google Cloud recently announced generative AI offerings that let developers tap into Google's foundation models, search expertise, and conversational AI technologies to create enterprise-grade generative AI applications. Google also offers its own [Bard chatbot]().

## Amazon.com, Inc. (Nasdaq: AMZN) — Market Cap US$1.08 Trillion

[Amazon]() operates e-commerce, cloud computing, and artificial intelligence platforms, such as Amazon Web Services (AWS) and Amazon Alexa, and offers pre-trained AI Services to integrate into customer applications and workflows.

## NVIDIA Corporation (Nasdaq: NVDA) — Market Cap US$664.7 Billion

[NVIDIA]() produces graphics processing units (GPUs) and artificial intelligence platforms, such as NVIDIA Omniverse and NVIDIA Clara. According to a report by research firm TrendForce, ChatGPT will require as many as 30,000 NVIDIA GPUs to operate, which costs between $10,000 and $15,000 for each GPU. As AI becomes more mainstream, NVIDIA looks to benefit from the GPU demand.

## Meta Platforms, Inc. (Nasdaq: META) — Market Cap US$537.2 Billion

[Meta](#) operates social media platforms and applications, such as Facebook, Instagram, and WhatsApp. It also develops artificial intelligence products and services, such as Facebook AI Research and Facebook Reality Labs.

## Adobe Inc. (Nasdaq: ADBE) — Market Cap US$116.5 Billion

[Adobe](#) provides software products and services for digital media creation and marketing, such as Adobe Creative Cloud and Adobe Sensei. Adobe Sensei is an artificial intelligence and machine learning technology developed by Adobe that powers its Creative Cloud suite of applications and uses AI and machine learning to automate tasks such as organizing, editing, and producing content.

## International Business Machines Corporation (NYSE: IBM) — Market Cap US$114.3 Billion

[IBM](#) provides IT solutions and services, such as IBM Cloud and IBM Watson. It also develops artificial intelligence products and services, such as IBM Project Debater and IBM AutoAI. In 2011, IBM's supercomputer Watson beat competitors on the popular game show Jeopardy!

## Final thoughts

The AI field is growing rapidly and has numerous applications in various industries. Major players offer a range of AI products and services, from cloud computing to chatbots and image, art, and music generators. NVIDIA, in particular, is poised to

benefit from the increasing demand for GPUs as AI becomes more mainstream. Despite concerns about AI taking over the world, investors are eagerly searching for ways to invest in this space.

---

# Trevor Jones of Lynx Global Intelligence on Using AI & Technology for Data Collection and Compliance

written by InvestorNews | January 16, 2024

In this InvestorIntel interview during PDAC 2023, Melissa Sanderson talks with Trevor Jones, Founder and CEO of [Lynx Global Intelligence](#) about its business intelligence ("BI") software platform that collects data from various sources such as sensors, satellite images, and field data, and puts it into one centralized database. This allows both people on the ground and managers in the C-suite to see all the data that pertains to compliance, ESG, health and safety, security and risk, and other monitored aspects of the business.

Trevor mentions that the platform uses artificial intelligence ("AI") tools to help its users query large amounts of data and support teams around the world. He also says that the platform can help mining companies comply with various ESG reporting by aligning data to pre-configured standards with a click of a button, saving clients time and money.

To access the full InvestorIntel interview, [click here](#).

Subscribe to the InvestorIntel YouTube channel by [clicking here](#).

## About Lynx Global Intelligence

Lynx Global Intelligence is a software provider helping mining explorers and producers capture ESG data at the asset level.

To learn more about Lynx Global Intelligence, [click here](#).

*Disclaimer:* This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the "Company" being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its

securities. Prospective investors are urged to review the Company's profile on [Sedar.com](Sedar.com) and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [info@investorintel.com](mailto:info@investorintel.com).

---

# The EYES have it, Early Stage Detection of Diabetes and Cardiovascular Disease

written by InvestorNews | January 16, 2024

Using Artificial Intelligence (AI) to better image and analyze the retina of the eye to detect early stage disease is a potential game changer in the prevention of blindness and cardiovascular diseases such as stroke, heart attack, and diabetic related disease.

Today's company is pioneering its work in this field with [USA clinical trials](#) commencing soon and a global commercialization rollout already underway. The company is [Diagnos Inc.](#) (TSXV: ADK | OTCQB: DGNOF) ("DIAGNOS").

DIAGNOS has developed an Artificial Intelligence (AI) tele-ophthalmology platform, which uses Computer Assisted Retina Analysis (CARA) to examine a patient's retina (back of the eye) for the early detection of diseases, such as diabetes, and conditions such as cardiovascular disease, hypertension and

stroke. CARA's image enhancement algorithms provide sharper, clearer and, thus, easier-to-analyze retinal images.

CARA has been cleared for commercialization by the following regulators: Health Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia). DIAGNOS already operates in 16 countries, with 131 screening sites, has 222,034 patients under their care, and has performed more than 400,000 retinographies around the world. DIAGNOS' CARA achieves great precision in diabetic retinopathy pre-diagnoses, reaching a sensitivity of 98.4%, specificity of 97.6% and a certainty of 97.9%.

**DIAGNOS uses an AI technology know as CARA to better analyze the retina of the eye, a key way to detect early cardiovascular disease**



Source: DIAGNOS website

**DIAGNOS achieves two firsts and an eight at the GAMMA (*G*laucoma gr*A*ding from *M*ulti-*M*odality im*A*ges) contest**

At the recent GAMMA competition, DIAGNOS achieved some stunning results including two firsts and an eighth place out of a total of 566 teams. Now that's super impressive!

The October 28, 2021 announcement stated: "DIAGNOS was the only one, of the top 8 teams, that competed with a marketed, commercialized system. DIAGNOS used the same platform that it currently uses for diabetic retinopathy screening, which is marketed worldwide, while the others were principally from academic institutions."

Key results included:

- Localization of macula fovea in fundus images. **(DIAGNOS placed 1st overall)**
- Segmentation of optic disc and cup in fundus images. **(DIAGNOS placed 1st overall)**
- Grading glaucoma using multi-modality data. **(DIAGNOS placed 8th overall)**

## USA clinical trial for the early detection and prevention of stroke using CARA-STROKE

On November 23 DIAGNOS announced: "DIAGNOS will start a clinical trial study in the USA commencing December 6th, 2021 for early detection and prevention of stroke using CARA-STROKE." The trial aims to confirm early Proof-of-Concept results that showed a strong potential in the early detection of stroke through the inspection and micro circulation analysis of the retina.

The upcoming USA clinic trial at the CommonSpirit Health Research Institute, Chattanooga Center for Neurologic Research LLC, is intended to further prove the effectiveness of DIAGNOS's CARA technology.

Note: CommonSpirit Health is a non-profit national Catholic healthcare system that operates 137 hospitals and more than 1,000 care sites across 21 states of the USA.

## Some facts about cardiovascular disease including stroke

- Stroke causes 1 out of every 20 deaths.
- The management of stroke represents a cost of around US$34 billion per year in the United States.
- According to the WHO, 15 million people suffer a stroke worldwide each year. Of these, 5 million die and another 5 million are permanently disabled.
- Europe averages approximately 650,000 stroke related

deaths each year.

- Worldwide Research Institutes says that the worldwide market size for stroke management will hit over $66 billion by 2023.

Source: [DIAGNOS announcement](#)

Clearly, the above facts speak volumes as to the need to diagnose cardiovascular disease early. And that is exactly what DIAGNOS does.

**Not just an idea, commercialization has begun**

As previously discussed in some detail [here](#), DIAGNOS commercialization is gaining momentum. Some examples include:

- [July 22, 2021](#) – DIAGNOS announced the official opening of the AI Assisted screening clinic at Magrabi Hospital in Saudi Arabia. Magrabi Hospitals and Centers has **thirty-four branches in the Middle East.**
- [July 28, 2021](#) – DIAGNOS announced a pilot in Spain with three franchisees from Opticalia Group.
- [August 16, 2021](#) – DIAGNOS announced signing a Memorandum of Understanding (MoU) for a distribution agreement with Essilor International. **Essilor International is the world's leading ophthalmic optics company.**
- [September 2, 2021](#) – DIAGNOS announced a three-year contract renewal with Optina Diagnostics providing a Telemedicine Platform to support their early detection of Alzheimer's Disease.
- [September 14, 2021](#) – DIAGNOS announced a 3-year contract with Cielo Vista Eye Clinic in Mexico.
- [September 16, 2021](#) – DIAGNOS announced a multi-year contract with Juarez Health & Medical Tourism Cluster in Mexico, who focuses on medical tourism and **serves between 10-12,000 patients a day.**

**Closing remarks**

DIAGNOS's CARA technology is clearly a winner. It has already won numerous global contracts and the recent GAMMA competition. Any potentially positive results from the upcoming CommonSpirit Health Research Institute clinical trial would just be icing on the cake.

With 15 million people suffering a stroke worldwide each year the time has come for better early diagnosis to allow earlier treatment and prevention, potentially reducing this terrible statistic.

Diagnos Inc. trades on a market cap of just [C$30 million](#) which seems very small when compared to the massive market for cardiovascular disease diagnosis. One to follow closely in the years ahead.

---

# Happy Earth Day — Look to these Stock to Support Mother Earth and Boost Your Portfolio Performance

written by InvestorNews | January 16, 2024

Investors are taking a deeper dive into corporations, looking beyond financial metrics and into a company's Environmental, Social, and Governance (ESG) standards as a measure of its commitment to all stakeholders, including a healthier planet.

Last year, Laurence Fink, the Founder and CEO of BlackRock, the world's largest asset manager, sent a letter to the CEOs of its invested companies and a second letter to its clients, addressing a focused mandate on sustainable investing. BlackRock sees climate risk as investment risk and plans to act ahead of the serious impacts of climate change by doubling its number of ESG funds.

Below are four companies where ESG has become a critical part of their business or a core belief in building a more sustainable business environment.

**1. [Cielo Waste Solutions Corp.](#) (CSE: CMC | OTCQB: CWSFF | FSE: C36)**

Cielo is literally turning garbage into gas; it doesn't get much greener than that!

Cielo, a waste to renewable fuel company, has a patented technology that converts landfill garbage into renewable high-grade diesel used in transport trucks and kerosene used for aviation jet and marine fuel.

After 16 years and C$75 million in research and development, and now a fully functional plant, Cielo is currently riding the "green wave" of investor interest in environmental tech, and the stock price has responded accordingly, up over 1,000% year-to-date.

Cielo is currently rolling out 10 facilities in North America over the next couple of years but with revenues expected from its first plant this year.

Read the latest story about Cielo [here](#).

**2. [mCloud Technologies Corp.](#) (TSXV: MCLD | OTCQB: MCLDF)**

mCloud helps businesses reduce energy waste, maximize energy production and get the most out of critical energy infrastructure. It focuses on using Artificial Intelligence (AI) to curb energy waste in buildings, maximize the energy production of wind turbines and extend the lifespan of critical energy infrastructure in a variety of different industries.

mCloud recently rolled out a new service that detects the leakage of gases during oil and gas production that will drive major carbon emission reductions for its customers in Alberta and the Middle East.

And yesterday, mCloud announced a partnership with three North American energy utility providers to offer its energy-saving solutions for HVAC and improved indoor air quality (IAQ) monitoring solutions that could target over one million commercial buildings in the U.S. and Canada.

Read about yesterday's news release [here](#).

## 3. [Nano One Materials Corp.](#) (TSXV: NNO)

Nano One Materials is a technology company with a patented and scalable industrial process for the production of low-cost, high-performance cathode materials used in lithium-ion batteries.

The cathode determines the battery's capacity and voltage, and can comprise 20% or more of the costs of a lithium-ion battery.

Nano One's proprietary "One Pot" furnace process creates a coated single crystal powder that protects the cathode from side reactions while allowing the transfer of lithium ions between electrolyte and cathode.

And, importantly, the process addresses ESG concerns around energy, waste, and carbon footprint in the lithium-ion battery

supply chain. It is an environmentally friendly process using limited water, and as it eliminates intermediate steps, it eliminates expensive and energy-intensive metal conversions and does not have a hazardous waste stream.

See the latest video about Nano One Materials [here](#).

**4. [Neo Lithium Corp.](#) (TSXV: NLC | OTCQX: NTTHF)**

Neo Lithium is advancing its 100% owned Tres Quebradas (3Q) project, a high-grade lithium brine lake and salar complex in Argentina. The 3Q Project is located in Latin America's "Lithium Triangle" and covers 350 KM2 (~86,500 acres) in the largest lithium-producing area in Argentina.

Last week, Neo Lithium [announced](#) that it engaged Golder Associates and the Argentinean National University of San Martin, to help with the ESG program as part of its Feasibility Study for 3Q project.

Waldo Perez, CEO of Neo Lithium said, "We take very seriously our compromise with all of our stakeholders and future generations, which in large part includes all aspects of ESG."

Neo Lithium wants to be at the low end of the $CO_2$ emission footprint when compared with other lithium brine projects.

Read the latest story about Neo Lithium [here](#).

# Happy Earth Day, Do Something Nice for Mother Earth.

# Predictiv AI – Using Artificial Intelligence to Solve "Real World" Problems

written by InvestorNews | January 16, 2024

## Predictiv AI's ThermalPass Part of a Back-to-Work Strategy

The U.S. Centers for Disease Control and Prevention (CDC) reported on Wednesday that approximately 123.9 million people in the U.S. have received at least one dose of a COVID-19 vaccine, representing about 37.3% of the total population.

While vaccination rates are increasing and new COVID-19 cases begin to decline, corporations are developing return-to-the-office strategies that address employees' safety expectations that include regular health and temperature checks.

**Temperature Checks Part of the New Workplace Health & Safety Protocols**

In order to avoid admitting employees with symptoms, buildings are employing screening measures including restricting entry to a single access point to facilitate temperature checks.

To reduce lineups and wait times, buildings are implementing fast methods of [fever detection](#), and ThermalPass by [Predictiv AI Inc.](#) (TSXV: PAI) is one solution.

**ThermalPass Fever Detection System**

Last year, Predictiv AI [launched ThermalPass](#), a fever-detection system that instantly screens for higher than normal body

temperatures that could be caused by a virus, such as COVID-19, in order to reduce the risk of spreading the contagion.

The ThermalPass stand-alone unit enhances public safety by providing fast, touch-free scanning of people at entranceways of high-traffic, public locations, and its waterproof design allows for both indoor and outdoor uses.

By integrating 24 medical-grade, non-invasive thermal sensors onto a metal frame, and taking 1200 readings per second, each unit can process one person per second and is perfect for mass screening applications at high-traffic locations such as airports, hospitals, office buildings, and sports stadiums.

**Growing Sales and Resellers**

This week, Predictiv AI reported that it [signed F2 Factor](#) to provide strategic support services to increase sales and distribution of ThermalPass.

This announcement follows a slew of partnerships signed earlier this year with other resellers including TFG Concepts (TFG), MCL Sustainable Cleaning Solutions (MCL), and Security Identification Systems Corp. (SISCO).

- [TFG](#) is a sales agency with more than 30 years of experience representing manufactures and brands and has partnered before with companies such as Canadian Tire, Costco, Home Depot, and Lowes.
- [MCL](#) plans to focus on the Education, Food Service, and Government sectors across Canada and has almost four decades of experience as a master distributor and their customers include Air Canada, the City of Toronto, and Sunnybrook Hospital.
- [SISCO](#) will integrate ThermalPass with its Fast-Pass® Visitor Management System to help with track-and-trace

efforts for building occupants and visitors.

Last week, Predictiv AI [announced](#) that it has installed multiple ThermalPass temperature scanning devices in Memorial Healthcare System hospital facilities in Broward County, Florida.

Memorial Healthcare is a provider of healthcare services in south Florida through a six-hospital network and various ancillary facilities. By integrating ThermalPass, it has helped eliminate forehead temperature checks and captures core employees' temperature in a more efficient manner.

Dawn de la Vega, Director of Nursing at Memorial Regional Hospital, stated, "With COVID-19 still threatening our community, it's important for us to continue using technology in a way that will help us maximize our team's time and provide quality and safe care to our community."

**Predictiv AI's ThermalPass Adopted by Memorial Healthcare System**



[Source:](#)

**Predictiv AI – Using Artificial Intelligence to Solve "Real World" Problems**

Predictiv AI is not a 1-product company but an innovator and strategic operator of emerging technology companies with a focus on artificial intelligence (AI), blockchain solutions, and the Internet-of-Things. The Company's R&D division, AI Labs Inc. (AI Labs), develops new products that solve real-world problems.

In March, Predictiv AI [announced](#) that it partnered with the Waterloo Artificial Intelligence Institute (Waterloo.AI) at the University of Waterloo to allow AI Labs to pursue its AI reach and commercialization efforts and leverage Waterloo.AI as an

extension of the Predictiv AI team.

Harold Godwin, Managing Director of Waterloo.AI, stated, "We are thrilled to have Predictiv AI join as a partner with Waterloo, this is a very exciting time for our university and Waterloo.AI, and we are grateful for the interest and ongoing support of our partners, including our newest, Predictiv AI."

The collaboration will allow AI Labs to access the artificial intelligence resources at Waterloo.AI, increasing the bandwidth in ideation, research, and development of solutions for real-world problems.

**Final Thoughts**

Predictiv AI helps businesses and organizations make smarter decisions using AI, deep machine learning, and data science.

As AI continues to be a disruptive technology, investors are looking for ways to profit from it and Predictiv AI could be an avenue for an AI investment.

With a market capitalization of less than C$11 million, there is still plenty of upside to this Canadian high-tech company.

---

# Warrant Exercise Builds Treasury for Perimeter's 2021 Commercialization Efforts

written by InvestorNews | January 16, 2024
Last week, [Perimeter Medical Imaging AI, Inc.](#) (TSXV: PINK)

announced that approximately 2.35 million warrants subject to an accelerated expiry were exercised, resulting in cash proceeds to the company of [over C$4.7 million](#).

Inclusive of the C$4.7 million raised from the exercise of accelerated warrants noted above, Perimeter received over C$7.28 million from the accelerated warrant exercise and can expect a further C$0.68 million if the remaining warrants are exercised by March 8.

The company plans to use the proceeds in its commercialization and development plans to bring Perimeter's medical imaging solution to the market in 2021. Perimeter's direct clinical sales efforts include a limited market release of the platform this quarter with a broader commercial launch in the second quarter.

**Perimeter's OTIS™ Platform**

Perimeter is a medical technology company utilizing ultra-high-resolution, real-time, advanced imaging tools in cancer surgeries to improve patient outcomes and reduce costs in the healthcare system.

Perimeter's OTIS™ platform, cleared by the FDA as an imaging tool, is a system that provides surgeons, radiologists, and pathologists with ultra-high-resolution, sub-surface image volumes to allow clinicians to visualize microscopic tissue structures during a clinical procedure.

**The Problem Being Solved**

[According to Dr. Alastair Thompson](#), MD, a surgical oncologist and professor at Baylor, *"One of the big problems in breast cancer surgery is that in about one in four women on whom we do a lumpectomy to remove cancer, we fail to get clear margins."*

Therefore doctors are searching for an effective and user-friendly tool to help identify that the breast cancer has been removed from a woman's breast.

Baylor is one of many institutions that is conducting a study with Perimeter's medical imaging system for providing real-time, high-resolution images of the removed tissues to assist cancer surgeons in making better decisions during operations.

Hospitals see this type of system could lead to a large improvement in patient care and reduce the need for second surgeries.

**Atlas AI Project — Artificial Intelligence (AI) / Machine Learning (ML) Tools**

In addition, Perimeter is advancing its advanced AI/ML image assessment tools through clinical development through its Atlas AI project.

Backed by a $7.4 million grant awarded by the Cancer Prevention and Research Institute of Texas (CPRIT), a leading state body that funds cancer research, the project will collect images of breast tumors from up to 400 patients for the purpose of training and testing Perimeter's "ImgAssist" AI technology to increase the efficiency of image review.

AI and analytics are seen as a way to address the inefficiencies and challenges that current operating rooms are facing in identifying cancerous tissues. According to the company, currently 1 in 4 patients who receive a lumpectomy has to come back for a second operation because the surgeon did not remove all of the cancer cells.

**Focus on Breast Cancer but Applications Beyond**

Cancer continues to grow amongst the population and puts a

burden on the healthcare system. According to the World Cancer Research Fund, breast cancer is the most common cancer in women worldwide, representing about 25 percent of all cancers in women.

In 2021, [Breastcancer.org](#) estimates that over 330,000 new cases of breast cancer are expected to be diagnosed in the United States and over 43,000 women are expected to die from breast cancer.

While currently focusing on deployments targeting breast cancer centers, OTIS™ has applications beyond breast cancer and into the larger multi-billion-dollar cancer surgery market.

**Final Thoughts**

According to a recent industry report from [Markets and Markets](#), the Surgical Imaging Market is projected to grow from US$1.8 billion in 2020 and reach US$2.4 billion by 2025, growing by 6.3% annually.

One of the major factors driving the growth of this market includes the increasing demand for minimally invasive procedures that Perimeter's platform addresses.

With the commercial launch of the product scheduled for this year, Perimeter has the potential to benefit from this growing market.

![x]

[SOURCE:](#)